Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$32.76 - $39.56 $11.9 Million - $14.4 Million
364,412 Added 451.09%
445,197 $15.6 Million
Q4 2023

Feb 09, 2024

BUY
$14.5 - $38.0 $620,339 - $1.63 Million
42,782 Added 112.58%
80,785 $3.07 Million
Q3 2023

Nov 09, 2023

BUY
$15.75 - $26.31 $570,024 - $952,211
36,192 Added 1998.45%
38,003 $697,000
Q2 2023

Aug 11, 2023

SELL
$16.96 - $27.82 $800,020 - $1.31 Million
-47,171 Reduced 96.3%
1,811 $47,000
Q1 2023

May 12, 2023

SELL
$18.45 - $27.14 $742,889 - $1.09 Million
-40,265 Reduced 45.12%
48,982 $924,000
Q4 2022

Feb 08, 2023

BUY
$20.18 - $33.33 $1.44 Million - $2.38 Million
71,452 Added 401.53%
89,247 $2.2 Million
Q3 2022

Nov 10, 2022

BUY
$11.58 - $24.73 $206,066 - $440,070
17,795 New
17,795 $319,000
Q2 2022

Aug 10, 2022

SELL
$8.52 - $25.26 $275,562 - $816,984
-32,343 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$19.89 - $43.18 $91,792 - $199,275
-4,615 Reduced 12.49%
32,343 $721,000
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $988,626 - $1.7 Million
36,958 New
36,958 $1.61 Million
Q2 2021

Aug 13, 2021

SELL
$14.69 - $27.52 $37,048 - $69,405
-2,522 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$16.27 - $41.26 $9,696 - $24,590
596 Added 30.94%
2,522 $51,000
Q4 2020

Feb 11, 2021

BUY
$15.96 - $50.0 $13,390 - $41,950
839 Added 77.18%
1,926 $64,000
Q3 2020

Nov 12, 2020

BUY
$16.77 - $20.65 $18,228 - $22,446
1,087 New
1,087 $20,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.